Evidence map›Paper›PMID 36865684›Full record

ReviewCancer nanotechnology2023

Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.

Muskan Goel, Yuri Mackeyev, Sunil Krishnan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer nanotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Evaluation ofACS omega · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Molecules (Basel, Switzerland) · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Muskan GoelAmity School of Applied Sciences, Amity University, Gurugram, Haryana 122413 India.
Yuri MackeyevVivian L. Smith Department of Neurosurgery, University of Texas Health Science Center, Houston, TX 77030 USA.
Sunil KrishnanVivian L. Smith Department of Neurosurgery, University of Texas Health Science Center, Houston, TX 77030 USA.

Funding

Rational translation of gold nanoparticle mediated radiosensitization tothe clinicR01CA257241 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Sang Hyun Cho, Sunil Krishnan · 2021 to 2026
$3.1M
Enhancing immune mediated head and neck cancer anti-tumor activity using nanoparticlesR01DE028105 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KRISHNAN, SUNIL, SKINNER, HEATH DEVIN · 2019 to 2023
$2.4M
Radiation response modulation of tumors using biocongjugated gold nanoparticlesR01CA155446 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHO, SANG HYUN, KRISHNAN, SUNIL · 2011 to 2015
$1.5M
NCI NIH HHS R01 CA155446NCI NIH HHS R01 CA257241NIDCR NIH HHS R01 DE028105
6 · The paper itself

Abstract

In the last three decades, radiopharmaceuticals have proven their effectiveness for cancer diagnosis and therapy. In parallel, the advances in nanotechnology have fueled a plethora of applications in biology and medicine. A convergence of these disciplines has emerged more recently with the advent of nanotechnology-aided radiopharmaceuticals. Capitalizing on the unique physical and functional properties of nanoparticles, radiolabeled nanomaterials or nano-radiopharmaceuticals have the potential to enhance imaging and therapy of human diseases. This article provides an overview of various radionuclides used in diagnostic, therapeutic, and theranostic applications, radionuclide production through different techniques, conventional radionuclide delivery systems, and advancements in the delivery systems for nanomaterials. The review also provides insights into fundamental concepts necessary to improve currently available radionuclide agents and formulate new nano-radiopharmaceuticals.

Indexed as

CancerNano-radiopharmaceuticalsNanotechnologyRadiolabeled nanomaterialRadionuclides

Identifiers

PMID36865684
PMCPMC9968708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.